Within the CharacTher project, we will focus on the Adeno-associated viruses (AAV) that are the most widely used vectors in gene therapies. Their application is regulated regardless of their origin and they encounter several restrictions prior to application to patients. Purity, quantity and quality are the most important attributes of the therapeutics that need to be assessed. The project aims to develop and implement novel analytical and processing approaches to improve the current state-of-the-art technologies for production, downstream purification and analytical characterization of the therapeutics.

Project ID: L4-3180
Duration: 1.10.2021 – 30.9.2024